Effect of NXY-059, a novel neuroprotectant, on the pharmacokinetics of a single dose of digoxin in healthy subjects

References

• Lopez AD, Mathers CD, Ezzati M, et al. Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data. Lancet 2006;367:1747–57
   PubMed Web of Science ®Google Scholar
• World Health Organization. The World Health Report 2004. Geneva: The World Health Organization, 2004
   Google Scholar
• American Heart Association. Heart Disease and Stroke Statistics – 2006 Update. Dallas, Texas: American Heart Association, 2006
   Google Scholar
• NINDS rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N Engl J Med 1995;333:1581–7
   Google Scholar
• Furlan AJ, Katzan IL, Caplan LR. Thrombolytic therapy in acute ischemic stroke. Curr Treat Options Cardiovasc Med 2003;5:171–80
   PubMedGoogle Scholar
• Maples KR, Ma F, Zhang YK. Comparison of the radical trapping ability of PBN, S-PPBN and NXY-059. Free Radic Res 2001;34: 417–26
   Google Scholar
• Chan PH. Reactive oxygen radicals in signaling and damage in the ischemic brain. J Cereb Blood Flow Metab 2001;21:2–14
   PubMed Web of Science ®Google Scholar
• Kuroda S, Tsuchidate R, Smith ML, et al. Neuroprotective effects of a novel nitrone, NXY-059, after transient focal cerebral ischemia in the rat. J Cereb Blood Flow Metab 1999;19:778–87
   PubMed Web of Science ®Google Scholar
• Sydserff SG, Borelli AR, Green AR, Cross AJ. Effect of NXY-059 on infarct volume after transient or permanent middle cerebral artery occlusion in the rat; studies on dose, plasma concentration and therapeutic time window. Br J Pharmacol 2002;135:103–12
   PubMed Web of Science ®Google Scholar
• Marshall JW, Duffin KJ, Green AR, Ridley RM. NXY-059, a free radical – trapping agent, substantially lessens the functional disability resulting from cerebral ischemia in a primate species. Stroke 2001;32:190–8
   PubMed Web of Science ®Google Scholar
• Marshall JWB, Cummings RM, Bowes LJ, et al. Functional and histological evidence for the protective effect of NXY-059 in a primate model of stroke when given 4 h after occlusion. Stroke 2003;34:2228–33
   PubMed Web of Science ®Google Scholar
• Lees KR, Zivin JA, Ashwood T, et al. NXY-059 for acute ischemic stroke. N Engl J Med 2006;354:588–600
   PubMed Web of Science ®Google Scholar
• Jonsson S, Cheng YF, Edenius C, et al. Population pharmaco-kinetic modelling and estimation of dosing strategy for NXY-059, a nitrone being developed for stroke. Clin Pharmacokinet 2005;44:863–78
   PubMed Web of Science ®Google Scholar
• AstraZeneca announces SAINT II trial results showed no efficacy in acute ischaemic stroke (http://www.astrazeneca.com/pressrelease/5279.aspx). AstraZeneca press release. 2006
   Google Scholar
• Edenius C, Strid S, Borgå O, et al. Pharmacokinetics of NXY-059, a nitrone-based free radical trapping agent, in healthy young and elderly subjects. J Stroke Cerebrovasc Dis 2002;11: 34–43
   Google Scholar
• Strid S, Borgå O, Edenius C, et al. Pharmacokinetics in renally impaired subjects of NXY-059, a nitrone-based, free-radical trapping agent developed for the treatment of acute stroke. Eur J Clin Pharmacol 2002;58:409–15
   PubMed Web of Science ®Google Scholar
• Wemer J, Cheng Y-F, Nilsson D, et al. Safety, tolerability and pharmacokinetics of escalating doses of NXY-059 in healthy young and elderly subjects. Curr Med Res Opin 2006;22: 1813–23
   Google Scholar
• Cheng Y-F, Strid S, Borgå O, et al. Effects of cimetidine and probenecid on renal clearance of NXY-059, a novel neuroprotectant: A phase I study to determine the transporter responsible for active secretion. Clin Pharmacol Ther 2006;79: 72
   Google Scholar
• Mooradian AD. Digitalis. An update of clinical pharmacokinetics, therapeutic monitoring techniques and treatment recommendations. Clin Pharmacokinet 1988;15:165–79
   PubMed Web of Science ®Google Scholar
• Drescher S, Glaeser H, Murdter T, et al. P-glycoprotein-mediated intestinal and biliary digoxin transport in humans. Clin Pharmacol Ther 2003;73:223–31
   PubMed Web of Science ®Google Scholar
• Kelly RA, Smith TW. Pharmacological treatment of heart failure. In: Hardman JG, Limbird LE, Molinoff PB, et al. eds).Goodman & Gilman’s The Pharmacological Basis of Therapeutics, 9th edn. 1996:817–18
   Google Scholar
• Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976;16:31–41
   PubMed Web of Science ®Google Scholar
• Parker RB, Yates CR, Soberman JE, Laizure SC. Effects of grapefruit juice on intestinal P-glycoprotein: evaluation using digoxin in humans. Pharmacotherapy 2003;23:979–87
   PubMed Web of Science ®Google Scholar
• Ochs HR, Greenblatt DJ, Bodem G, Harmatz JS. Dose-independent pharmacokinetics of digoxin in humans. Am Heart J 1978;96:507–11
   PubMed Web of Science ®Google Scholar
• Martin PD, Kemp J, Dane AL, et al. No effect of rosuvastatin on the pharmacokinetics of digoxin in healthy volunteers. J Clin Pharmacol 2002;42:1352–7
   PubMed Web of Science ®Google Scholar
• Sarich TC, Schutzer KM, Wollbratt M, et al. No pharmacokinetic or pharmacodynamic interaction between digoxin and the oral direct thrombin inhibitor ximelagatran in healthy volunteers. J Clin Pharmacol 2004;44:935–41
   PubMed Web of Science ®Google Scholar
• Roman D, Bramson C, Ouellet D, et al. Effect of lasofoxifene on the pharmacokinetics of digoxin in healthy postmenopausal women. J Clin Pharmacol 2005;45:1407–12
   PubMed Web of Science ®Google Scholar
• Steimer W, Muller C, Eber B. Digoxin assays: frequent, substantial, and potentially dangerous interference by spironolactone, canrenone, and other steroids. Clin Chem 2002;48:507–16
   Google Scholar